Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | FNTA | P49354 | 6/20 | 0.59 |
| ▸ | FNTB | P49356 | 6/20 | 0.59 |
| ▸ | AR | P10275 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.57 |
| ▸ | PGR | P06401 | 4/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anecortave Acetate SCHEMBL94110 | 1.00 | NR3C1 (1.00) | NR3C1FNTAFNTBARKMT2A | |
| Anecortave Acetate SCHEMBL8470303 | 1.00 | NR3C1 (1.00) | NR3C1FNTAFNTBARKMT2A | |
| Anecortave Acetate SCHEMBL14612532 | 1.00 | NR3C1 (1.00) | NR3C1FNTAFNTBARKMT2A | |
| Anecortave Acetate SCHEMBL8472390 | 0.96 | NR3C1 (0.93) | NR3C1FNTAFNTBARKMT2A | |
| SCHEMBL25177986 | 0.92 | NR3C1 (0.85) | NR3C1FNTAFNTBARKMT2A | |
| SCHEMBL25184624 | 0.92 | NR3C1 (0.85) | NR3C1FNTAFNTBARKMT2A | |
| SCHEMBL23974865 | 0.92 | NR3C1 (0.84) | NR3C1FNTAFNTBARKMT2A | |
| SCHEMBL25181307 | 0.91 | NR3C1 (0.83) | NR3C1FNTAFNTBARKMT2A | |
| SCHEMBL3437593 | 0.91 | NR3C1 (0.83) | NR3C1FNTAFNTBARKMT2A | |
| SCHEMBL3437604 | 0.90 | NR3C1 (0.82) | NR3C1FNTAFNTBARKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145657-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20240307411-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240285650-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220324902-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2022-10-13 | — | — | US | disclosed |
| US-8058266-B2 | Methods and compositions for treatment of macular and retinal disease | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058266-B2 | Methods and compositions for treatment of macular and retinal disease | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2011127048-A2 | NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE | VALIDUS BIOPHARMA (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2010-04-08 | — | — | US | disclosed |
| US-20070259843-A1 | Methods and Compositions for Treatment of Macular and Retinal Disease | MARCUS, DENNIS M. | 2007-11-08 | — | — | US | disclosed |
| US-20070259843-A1 | Methods and Compositions for Treatment of Macular and Retinal Disease | MARCUS, DENNIS M. | 2007-11-08 | — | — | US | disclosed |
| US-7259180-B2 | Methods and compositions for treatment of macular and retinal disease | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259180-B2 | Methods and compositions for treatment of macular and retinal disease | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307411-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 11/4885FNTA 323/4885FNTB 341/4885 |
| US-20240285650-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885FNTA 2077/4885FNTB 1122/4885 |
| US-20220324902-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 11/4885FNTA 323/4885FNTB 341/4885 |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | NFKBIA, NFKB2, IKBKG | NR3C1 10/4885FNTA 532/4885FNTB 293/4885 |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885FNTA 2077/4885FNTB 1122/4885 |
| US-20070259843-A1 | Methods and Compositions for Treatment of Macular and Retinal Disease | RB1, ALDH1A2, CDK4 | NR3C1 2115/4885FNTA 1729/4885FNTB 4007/4885 |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885FNTA 2077/4885FNTB 1122/4885 |
| US-20250145657-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 11/4885FNTA 323/4885FNTB 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.